Topic

Cigna

A collection of 1335 issues

How to Renew iLink® Corneal Cross-Linking Coverage with Cigna in New Jersey: Timeline, Documentation & Appeals

Answer Box: Quick Guide to iLink® Renewal with Cigna in New Jersey Cigna requires annual reapproval for iLink® corneal cross-linking with documented keratoconus progression. Start renewal preparation 60 days before your current approval expires. Submit reauthorization 2-4 weeks early with updated corneal topography, pachymetry, and ophthalmologist progress notes. If denied,
5 min read

Getting Somatuline Depot (Lanreotide) Covered by Cigna in Texas: Prior Authorization, Appeals, and Cost-Saving Strategies

Quick Answer: Cigna requires prior authorization for Somatuline Depot (lanreotide) with documentation of octreotide trial unless contraindicated. Your endocrinologist/oncologist must submit medical necessity forms within 72 hours for standard review. If denied, file internal appeal within 180 days, then external review through Texas IRO within 4 months. Commercial patients
6 min read

Work With Your Doctor to Get Tecentriq (atezolizumab) Covered by Cigna in North Carolina: Complete Provider Collaboration Guide

Answer Box: Getting Tecentriq Covered by Cigna in North Carolina Tecentriq (atezolizumab) requires prior authorization from Cigna, which reviews requests through eviCore healthcare within 72 hours for standard cases or 24 hours for urgent cancer situations. Your oncologist must document diagnosis, PD-L1 testing results (when required), prior therapies, and NCCN
6 min read

How to Get Cabometyx (cabozantinib) Covered by Cigna in Washington: Complete Guide to Prior Authorization, Appeals, and Cost Assistance

Quick Answer: Cabometyx (cabozantinib) requires prior authorization from Cigna in Washington. Your oncologist submits documentation through CoverMyMeds or ExpressPAth with diagnosis, prior therapy failures, and medical necessity justification. Standard approval takes 72 hours; denials can be appealed through Cigna's internal process, then external review via Washington's
6 min read